{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:28Z","timestamp":1793192488517,"version":"4.5.0"},"reference-count":129,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Cefepime is recommended for the treatment of febrile neutropenia and gram-negative infections at moderate risk of ampicillin resistance locus C \u03b2-lactamase production. Concerns regarding cefepime\u2019s safety have been raised in the literature without firm conclusions.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To conduct a systematic review and bayesian random-effects meta-analysis of all randomized clinical trials (RCTs) comparing cefepime with other \u03b2-lactams for all-cause mortality.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n Cochrane Central Register of Controlled Trials, Medline, Embase, Web of Science, World Health Organization\u2013International Clinical Trials Registry Platform, ClinicalTrials.gov, and LILACS were searched from inception to May 25, 2026.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Randomized clinical trials of children and adults comparing either (1) cefepime monotherapy vs any \u03b2-lactam monotherapy or (2) combination therapy of cefepime and a second drug vs \u03b2-lactam and the same second drug. Studies of prophylactic cefepime or cefepime and \u03b2-lactamase inhibitor combinations were excluded.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Two independent reviewers extracted data and assessed the risk of bias using the Cochrane risk-of-bias tool, version 2.0.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was all-cause mortality (30-day or closest reported). Odds of mortality were synthesized using a hierarchical bayesian random-effects model on the log-odds scale. The posterior probabilities of increased mortality (odds ratio [OR] &amp;gt;1) with cefepime for the overall analysis and relevant subgroups were examined. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations framework.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Synthesis of 110 trials including 22\u202f608 patients (cefepime: 11 726 patients [approximately 56% male]; comparator \u03b2-lactam: 10 882 patients [approximately 56% male]) showed a 94.4% posterior probability that the pooled OR mortality exceeded 1 with cefepime use compared with other \u03b2-lactams (778 [6.6%] vs 674 [6.2%]; OR, 1.10, 95% credible interval, 0.98-1.24). Meta-analysis of published peer-reviewed RCTs (73 trials, 15\u202f411 patients) showed that cefepime was associated with a 98.6% posterior probability of higher mortality compared with other \u03b2-lactams (OR, 1.17; 95% credible interval, 1.02-1.34). Posterior distributions generally favored higher odds of mortality across all comparator \u03b2-lactams, across all clinical indications, and with doses of 2 g or more every 12 hours.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This systematic review and bayesian meta-analysis found that cefepime was associated with higher odds of all-cause mortality compared with other \u03b2-lactams. These findings support a nuanced discussion of cefepime\u2019s safety in guidance statements.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.33017","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:00:29Z","timestamp":1789052429000},"page":"e2633017","source":"Crossref","is-referenced-by-count":2,"title":["Cefepime and Mortality"],"prefix":"10.1001","volume":"9","author":[{"given":"Zahra N.","family":"Sohani","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Medical Microbiology, Department of Medicine, H\u00f4pital Maisonneuve-Rosemont, CIUSSS de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Jia","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avideh","family":"Afshar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bander A.","family":"Assiri","sequence":"additional","affiliation":[{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Clinical Pharmacy Department, College of Pharmacy, King Khalid University, Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gore","sequence":"additional","affiliation":[{"name":"Schulich Library of Physical Sciences, Life Sciences, and Engineering, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lieu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana","family":"Serero","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus","family":"Hamilton","sequence":"additional","affiliation":[{"name":"School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lawandi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur M.","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Butler-Laporte","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Schulich Library of Physical Sciences, Life Sciences, and Engineering, Montreal, Quebec, Canada"},{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"6","key":"zoi260902r1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance.","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"zoi260902r2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/cid\/cit395","article-title":"The use of cefepime for treating AmpC \u00df-lactamase-producing Enterobacteriaceae.","volume":"57","author":"Tamma","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi260902r3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10096-023-04715-5","article-title":"Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections.","volume":"43","author":"Herrmann","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"zoi260902r4","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"zoi260902r5","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines.","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"zoi260902r6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections.","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi260902r7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis.","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"zoi260902r8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/jac\/dku001","article-title":"Effect of cefepime dose on mortality of patients with gram-negative bacterial bloodstream infections: a prospective cohort study.","volume":"69","author":"Alves","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"zoi260902r9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx113","article-title":"The dose-dependent efficacy of cefepime in the empiric management of febrile neutropenia: a systematic review and meta-analysis.","volume":"4","author":"Andreatos","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"zoi260902r10","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"zoi260902r11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/phar.2766","article-title":"Adequacy of cefepime concentrations in the early phase of critical illness: a case for precision pharmacotherapy.","volume":"43","author":"Barreto","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"4","key":"zoi260902r12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx170","article-title":"Characterizing cefepime neurotoxicity: a systematic review.","volume":"4","author":"Appa","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"zoi260902r13","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1093\/jac\/dkac271","article-title":"Cefepime-induced neurotoxicity: systematic review.","volume":"77","author":"Maan","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"zoi260902r14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review.","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"issue":"9","key":"zoi260902r15","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/ndt\/14.9.2265","article-title":"Cefepime-related neurotoxicity in a haemodialysis patient.","volume":"14","author":"Wong","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"zoi260902r16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use.","volume":"51","author":"Kim","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi260902r17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/0897190017743134","article-title":"The role of cefepime in the treatment of extended-spectrum beta-lactamase infections.","volume":"32","author":"Patel","year":"2019","journal-title":"J Pharm Pract"},{"issue":"4","key":"zoi260902r18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1086\/655132","article-title":"Cefepime and death: reality to the rescue.","volume":"51","author":"Freifeld","year":"2010","journal-title":"Clin Infect Dis"},{"key":"zoi260902r19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fped.2018.00046","article-title":"Cefepime efficacy and safety in children: a systematic review and meta-analysis.","volume":"6","author":"Jan","year":"2018","journal-title":"Front Pediatr"},{"issue":"3","key":"zoi260902r20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jpeds.2010.03.023","article-title":"Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis.","volume":"157","author":"Adderson","year":"2010","journal-title":"J Pediatr"},{"issue":"6","key":"zoi260902r21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/jac\/dkr138","article-title":"Is cefepime safe for clinical use? A bayesian viewpoint.","volume":"66","author":"Kalil","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"6-7","key":"zoi260902r22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3109\/00365540903555349","article-title":"Cefepime and mortality: a real issue?","volume":"42","author":"Mebis","year":"2010","journal-title":"Scand J Infect Dis"},{"issue":"7","key":"zoi260902r23","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1086\/597264","article-title":"Cefepime therapy and all-cause mortality.","volume":"48","author":"Nguyen","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi260902r24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamainternmed.2024.0581","article-title":"Mortality of patients with sepsis administered piperacillin-tazobactam vs cefepime.","volume":"184","author":"Chanderraj","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi260902r25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews.","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"11","key":"zoi260902r26","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1086\/657247","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use.","volume":"51","author":"Leibovici","year":"2010","journal-title":"Clin Infect Dis"},{"key":"zoi260902r27","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"zoi260902r29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"zoi260902r30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/pbc.25178","article-title":"Comparison between piperacillin\/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: a prospective, randomized study.","volume":"62","author":"Sano","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"zoi260902r31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10156-012-0466-8","article-title":"Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.","volume":"19","author":"Nakagawa","year":"2013","journal-title":"J Infect Chemother"},{"issue":"3","key":"zoi260902r32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/08880010500506370","article-title":"Monotherapy with piperacillin\/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.","volume":"23","author":"Corapcioglu","year":"2006","journal-title":"Pediatr Hematol Oncol"},{"issue":"14","key":"zoi260902r33","first-page":"2006","article-title":"Multicenter, double-blind, randomized clinical trial of parenterally administered cefoselis versus cefepime for the treatment of acute bacterial infections.","volume":"18","author":"Liu","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"zoi260902r34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: An R package for bayesian multilevel models using Stan.","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"issue":"5","key":"zoi260902r35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v100.i05","article-title":"Bayesian item response modeling in R with brms and Stan.","volume":"100","author":"B\u00fcrkner","year":"2021","journal-title":"J Stat Softw"},{"issue":"2","key":"zoi260902r36","first-page":"102","article-title":"Comparison of cefepime and meropenem use in treatment of neutropenic fever.","volume":"46","author":"Atay","year":"2004","journal-title":"G\u00fclhane Med J"},{"issue":"8","key":"zoi260902r37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/00365540410017590","article-title":"A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.","volume":"36","author":"Cherif","year":"2004","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"zoi260902r38","first-page":"18","article-title":"A prospective study of cefepime versus ticarcilline\/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients.","volume":"61","author":"Naseem","year":"2011","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"zoi260902r39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/pbc.22100","article-title":"Piperacillin\/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study.","volume":"53","author":"Uygun","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"zoi260902r40","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28251","article-title":"Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.","volume":"67","author":"Avil\u00e9s-Robles","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"zoi260902r41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00006454-200203000-00009","article-title":"Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.","volume":"21","author":"Chuang","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"zoi260902r42","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000007228","article-title":"A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.","volume":"45","author":"Wang","year":"1999","journal-title":"Chemotherapy"},{"issue":"4","key":"zoi260902r43","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ajh.10236","article-title":"Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.","volume":"71","author":"Tamura","year":"2002","journal-title":"Am J Hematol"},{"issue":"4","key":"zoi260902r44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jiac.2016.01.005","article-title":"The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.","volume":"22","author":"Fujita","year":"2016","journal-title":"J Infect Chemother"},{"issue":"1","key":"zoi260902r45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jiac.2014.08.026","article-title":"Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: a multicenter prospective randomized trial.","volume":"21","author":"Nakane","year":"2015","journal-title":"J Infect Chemother"},{"issue":"1","key":"zoi260902r46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/jjco\/hym151","article-title":"Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.","volume":"38","author":"Kwon","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"zoi260902r47","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/pbc.25148","article-title":"A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients.","volume":"61","author":"Sarashina","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"zoi260902r48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/00365540110076679","article-title":"Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.","volume":"33","author":"Erman","year":"2001","journal-title":"Scand J Infect Dis"},{"issue":"3-4","key":"zoi260902r49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12288-008-0007-x","article-title":"Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies.","volume":"23","author":"Ghalaut","year":"2007","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"zoi260902r50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/clinids\/24.1.41","article-title":"Cefepime\/amikacin versus ceftazidime\/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study.","volume":"24","author":"Cordonnier","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi260902r51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10096-010-0879-1","article-title":"Low-dose \u00df-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin\/tazobactam, a randomized trial.","volume":"29","author":"G\u00f3mez","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"zoi260902r52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/jac\/42.4.511","article-title":"Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia.","volume":"42","author":"Biron","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"zoi260902r53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/08880010500506867","article-title":"Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.","volume":"23","author":"Oguz","year":"2006","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"zoi260902r54","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/pbc.10442","article-title":"Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours.","volume":"42","author":"Kutluk","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"zoi260902r55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0049475515617571","article-title":"A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.","volume":"46","author":"Aamir","year":"2016","journal-title":"Trop Doct"},{"issue":"4","key":"zoi260902r56","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/mpo.1107","article-title":"Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.","volume":"36","author":"Kebudi","year":"2001","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"zoi260902r58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/jac\/dkf087","article-title":"Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.","volume":"50","author":"Sanz","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"zoi260902r59","first-page":"324","article-title":"Piperacillin\/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.","volume":"3","author":"B\u00f6hme","year":"1998","journal-title":"Eur J Med Res"},{"issue":"4","key":"zoi260902r60","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1086\/505393","article-title":"A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.","volume":"43","author":"Bow","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi260902r61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00277-001-0392-9","article-title":"A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin.","volume":"81","author":"Cornely","year":"2002","journal-title":"Ann Hematol"},{"issue":"5","key":"zoi260902r62","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/cncr.11613","article-title":"Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.","volume":"98","author":"Raad","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"zoi260902r63","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/00006454-200103000-00036","article-title":"Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.","volume":"20","author":"Mustafa","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"zoi260902r64","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1345\/aph.10001","article-title":"Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer.","volume":"34","author":"Chandrasekar","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"6A","key":"zoi260902r65","doi-asserted-by":"publisher","first-page":"83S","DOI":"10.1016\/S0002-9343(96)00113-1","article-title":"Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.","volume":"100","author":"Ramphal","year":"1996","journal-title":"Am J Med"},{"issue":"1","key":"zoi260902r66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/clinids\/20.1.56","article-title":"Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia.","volume":"20","author":"Schrank","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"6A","key":"zoi260902r67","doi-asserted-by":"publisher","first-page":"52S","DOI":"10.1016\/S0002-9343(96)00108-8","article-title":"Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.","volume":"100","author":"Holloway","year":"1996","journal-title":"Am J Med"},{"key":"zoi260902r68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jac\/32.suppl_B.175","article-title":"International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.","volume":"32","author":"Hoepelman","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"zoi260902r69","first-page":"159","article-title":"Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.","volume":"35","author":"Huang","year":"2002","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"zoi260902r70","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0924-8579(98)00040-5","article-title":"Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment.","volume":"10","author":"Chang","year":"1998","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"zoi260902r71","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0732-8893(99)00085-1","article-title":"Cefepime versus ceftazidime for the treatment of serious bacterial infections.","volume":"35","author":"Ponce-de-Le\u00f3n","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"zoi260902r72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1128\/AAC.38.3.415","article-title":"Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.","volume":"38","author":"Kieft","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"zoi260902r73","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial.","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"zoi260902r74","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.42.4.729","article-title":"Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia.","volume":"42","author":"Zervos","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"zoi260902r75","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1532-5415.2007.01152.x","article-title":"Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.","volume":"55","author":"Paladino","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"zoi260902r76","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/jac\/28.4.569","article-title":"A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.","volume":"28","author":"Edelstein","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"zoi260902r77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jmii.2015.02.461","article-title":"Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.","volume":"34","author":"Lin","year":"2001","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"zoi260902r78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jiac.2019.08.005","article-title":"Cefepime vs. meropenem for moderate-to-severe pneumonia in patients at risk for aspiration: an open-label, randomized study.","volume":"26","author":"Oi","year":"2020","journal-title":"J Infect Chemother"},{"issue":"11","key":"zoi260902r79","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"zoi260902r80","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10096-006-0193-0","article-title":"Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.","volume":"25","author":"Yakovlev","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"zoi260902r81","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0750-7658(99)90093-X","article-title":"Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study.","volume":"18","author":"Beaucaire","year":"1999","journal-title":"Ann Fr Anesth Reanim"},{"issue":"4","key":"zoi260902r82","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1179\/joc.1999.11.4.273","article-title":"A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia.","volume":"11","author":"Bonfitto","year":"1999","journal-title":"J Chemother"},{"issue":"4","key":"zoi260902r83","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jac\/48.4.527","article-title":"Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial.","volume":"48","author":"Cordero","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"zoi260902r84","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/jac\/32.suppl_B.187","article-title":"Cefepime versus cefotaxime in the treatment of lower respiratory tract infections.","volume":"32","author":"Barckow","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"zoi260902r85","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/jac\/43.4.549","article-title":"Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin.","volume":"43","author":"Grossman","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"zoi260902r86","first-page":"117","article-title":"Cefepime\/clindamycin vs. ceftriaxone\/clindamycin for the empiric treatment of poisoned patients with aspiration pneumonia.","volume":"79","author":"Talaie","year":"2008","journal-title":"Acta Biomed"},{"issue":"3","key":"zoi260902r87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/joc.1997.9.3.213","article-title":"Cefepime versus ceftazidime in the treatment of lower respiratory tract infections.","volume":"9","author":"Aufiero","year":"1997","journal-title":"J Chemother"},{"issue":"6A","key":"zoi260902r88","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.1016\/S0002-9343(96)00109-X","article-title":"A new therapeutic option for the treatment of pneumonia.","volume":"100","author":"McCabe","year":"1996","journal-title":"Am J Med"},{"key":"zoi260902r89","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/32.suppl_B.165","article-title":"A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections.","volume":"32","author":"L\u00e9ophonte","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"zoi260902r90","doi-asserted-by":"publisher","first-page":"859","DOI":"10.11150\/kansenshogakuzasshi1970.66.859","article-title":"A comparative study of cefepime for bacterial pneumonia.","volume":"66","author":"Saito","year":"1992","journal-title":"Kansenshogaku Zasshi"},{"issue":"7","key":"zoi260902r91","doi-asserted-by":"publisher","first-page":"886","DOI":"10.11150\/kansenshogakuzasshi1970.66.886","article-title":"A comparative study of cefepime for chronic respiratory tract infections.","volume":"66","author":"Saito","year":"1992","journal-title":"Kansenshogaku Zasshi"},{"issue":"1","key":"zoi260902r92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1179\/136485908X252151","article-title":"Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study.","volume":"102","author":"Shahid","year":"2008","journal-title":"Ann Trop Med Parasitol"},{"issue":"8","key":"zoi260902r93","doi-asserted-by":"publisher","first-page":"e00023","DOI":"10.1128\/AAC.00023-19","article-title":"Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia.","volume":"63","author":"Liu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"zoi260902r94","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"7","key":"zoi260902r95","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/00006454-199807000-00012","article-title":"Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases.","volume":"17","author":"Schaad","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"zoi260902r96","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children =3 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial.","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"zoi260902r97","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0011-393X(95)85056-2","article-title":"Randomized, double-blind comparison of cefepime and ceftazidime therapy for urinary tract infection.","volume":"56","author":"Preheim","year":"1995","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6A","key":"zoi260902r98","doi-asserted-by":"publisher","first-page":"76S","DOI":"10.1016\/S0002-9343(96)00112-X","article-title":"Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections.","volume":"100","author":"Sharifi","year":"1996","journal-title":"Am J Med"},{"issue":"6A","key":"zoi260902r99","doi-asserted-by":"publisher","first-page":"90S","DOI":"10.1016\/S0002-9343(96)00111-8","article-title":"Current and future management of serious skin and skin-structure infections.","volume":"100","author":"Schwartz","year":"1996","journal-title":"Am J Med"},{"key":"zoi260902r100","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/jac\/32.suppl_B.195","article-title":"Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections.","volume":"32","author":"Newton","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"zoi260902r101","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1128\/AAC.35.11.2371","article-title":"Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.","volume":"35","author":"Gentry","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"zoi260902r102","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/liv.12985","article-title":"A randomized open label study of \u2018imipenem vs. cefepime\u2019 in spontaneous bacterial peritonitis.","volume":"36","author":"Jindal","year":"2016","journal-title":"Liver Int"},{"issue":"11","key":"zoi260902r103","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/INF.0000000000000859","article-title":"Safety and tolerability of doripenem in hospitalized children with complicated intra-abdominal infection, complicated urinary tract infections and pneumonia.","volume":"34","author":"Cannavino","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"zoi260902r104","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00006454-200103000-00035","article-title":"Cefepime in the empiric treatment of meningitis in children.","volume":"20","author":"S\u00e1ez-Llorens","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"zoi260902r105","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1128\/AAC.39.4.937","article-title":"Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children.","volume":"39","author":"S\u00e1ez-Llorens","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"zoi260902r107","first-page":"312","article-title":"Randomized comparison of cefepime\/amikaicin versus ceftazidime\/amikaicin as empiric treatment for febrile neutropenia in cancer patients.","volume":"6","author":"Jehn","year":"1998","journal-title":"Support Care Cancer"},{"issue":"9","key":"zoi260902r108","first-page":"1199","article-title":"Therapeutic effects of cefepime and sulbactam\/cefoperazone on moderate and severe respiratory tract infection in children.","volume":"25","author":"Huang","year":"2005","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"key":"zoi260902r109","first-page":"636","article-title":"Cefepime vs cefotaxime in the treatment of pneumonia.","volume":"15","author":"Willis","year":"1998","journal-title":"Infect Med"},{"key":"zoi260902r115","article-title":"Clinical efficacy and cost-effectiveness analysis of cefepime or piperacillin\/tazobactam both with ciprofloxacin in MICU patients with severe pneumonia.","volume":"54","author":"Lee","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"zoi260902r116","first-page":"92","article-title":"Comparison of the efficacy and safety between cefepime and ceftazidime in the treatment of the moderate to severe low-respiratory tract infection.","volume":"8","author":"Jiang","year":"2003","journal-title":"Chin J Clin Pharmacol Therapeut"},{"issue":"7650","key":"zoi260902r118","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"zoi260902r119","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"zoi260902r120","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"zoi260902r121","doi-asserted-by":"publisher","first-page":"R264","DOI":"10.1186\/cc13094","article-title":"Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy.","volume":"17","author":"Fugate","year":"2013","journal-title":"Crit Care"},{"issue":"3","key":"zoi260902r122","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmi.2019.06.028","article-title":"Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study.","volume":"26","author":"Boschung-Pasquier","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"zoi260902r123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12941-017-0227-8","article-title":"Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.","volume":"16","author":"Su","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"12","key":"zoi260902r124","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.","volume":"51","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"zoi260902r125","doi-asserted-by":"publisher","first-page":"e00745","DOI":"10.1128\/AAC.00745-20","article-title":"Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing.","volume":"64","author":"Al-Shaer","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"zoi260902r126","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates.","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"zoi260902r127","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad034","article-title":"High-dose cefepime vs carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC \u00df-lactamase production.","volume":"10","author":"Kunz Coyne","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi260902r128","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3947\/ic.2017.49.1.62","article-title":"Impact of revised broad-spectrum cephalosporin clinical and laboratory standards institute breakpoints on susceptibility in Enterobacteriaceae producing AmpC \u00df-lactamase.","volume":"49","author":"Park","year":"2017","journal-title":"Infect Chemother"},{"issue":"1","key":"zoi260902r129","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/cid\/ciaf317","article-title":"Does piperacillin-tazobactam increase mortality risk compared with cefepime? Collider bias and the importance of assumptions in instrumental variable analyses.","volume":"82","author":"Hamilton","year":"2026","journal-title":"Clin Infect Dis"},{"key":"zoi260902r28","volume-title":"Cochrane Handbook for Systematic Review of Interventions Version 6.3","author":"Higgins","year":"2022"},{"key":"zoi260902r57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-642-60443-0_13","volume-title":"Febrile Neutropenia","author":"Breen","year":"1997"},{"key":"zoi260902r110","author":"Cornely","year":"2001"},{"key":"zoi260902r111","author":"Mallet","year":"1997"},{"key":"zoi260902r112","author":"O\u2019Ryan","year":"1996"},{"key":"zoi260902r113","author":"Gentry","year":"1992"},{"key":"zoi260902r114","author":"Gomez","year":"2001"},{"key":"zoi260902r106","unstructured":"Glauser? M, Dekker? AW, Van Marwijkkooy? M, et al. A multicenter comparative study of cefepime vs. ceftazidime as empiric therapy in the treatment of febrile episodes in neutropenic patients. 1997. Accessed March 30, 2007. https:\/\/ouci.dntb.gov.ua\/en\/works\/4MomMav9\/"},{"key":"zoi260902r117","unstructured":"Aoun? M, Boogaerts? MA, Bosly? AJ, Schots? H. A multicenter, randomized, prospective, comparative study of cefepime plus vancomycin versus ceftazidime plus vancomycin as empiric therapy in the treatment of febrile episodes in granulocytopenic patients with hematological malignancies. Accessed March 30, 2007. https:\/\/ouci.dntb.gov.ua\/en\/works\/4MomMav9\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853883\/sohani_2026_oi_260902_1790700000.79505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:00:20Z","timestamp":1790701220000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853883"}},"subtitle":["A Systematic Review and Bayesian Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":129,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.33017","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}